Compounders Research Compare

Absci Corporation(ABSI)

Biotechnology · Vancouver, WA

$10.79-0.74 (-6.42%)

Delayed quote: Oct 6, 2026, 12:00 PM EDT

About Absci Corporation

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

Vancouver, WA

140 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sean McClain

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T16:00:32.118Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:00:32.118Z.

Quote observation: 2026-10-06T16:00:19.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,827,826,000
Total debt · period ending 2026-06-30: 3,679,000
Cash · period ending 2026-06-30: 107,865,000
TTM free cash flow · period ending 2026-06-30: -109,180,000

FMP input reference: 6c856baf2af26ca9326fa79b8c43a58fbb1378fdf70f4049426595b89831cd0b

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ABSI EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ABSI Competitors' EV/FCF Ratio

Absci Corporation

Current

Market Cap

$1.83B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LeMaitre Vascular, Inc.

Market Cap

$1.82B

EV/FCF Ratio

26.87x

TTM Avg

33.52x

3Y Avg

48.28x

5Y Avg

46.71x

Novocure Ltd

Market Cap

$1.84B

EV/FCF Ratio

N/A

TTM Avg

434.55x

3Y Avg

309.38x

5Y Avg

391.85x

Astrana Health, Inc.

Market Cap

$1.84B

EV/FCF Ratio

15.24x

TTM Avg

17.23x

3Y Avg

28.18x

5Y Avg

30.02x

Palvella Therapeutics, Inc.

Market Cap

$1.86B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Generate Biomedicines, Inc.

Market Cap

$1.79B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Novavax, Inc.

Market Cap

$1.87B

EV/FCF Ratio

N/A

TTM Avg

19.57x

3Y Avg

82.87x

5Y Avg

82.87x

Azenta, Inc.

Market Cap

$1.89B

EV/FCF Ratio

177.04x

TTM Avg

49.00x

3Y Avg

83.04x

5Y Avg

82.00x

BioLife Solutions, Inc.

Market Cap

$1.89B

EV/FCF Ratio

N/A

TTM Avg

539.27x

3Y Avg

437.29x

5Y Avg

621.70x

Agios Pharmaceuticals, Inc.

Market Cap

$1.89B

EV/FCF Ratio

N/A

TTM Avg

34.54x

3Y Avg

34.54x

5Y Avg

34.54x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Absci Corporation (ABSI)	$1.83B	N/A	N/A	N/A	N/A
LeMaitre Vascular, Inc. (LMAT)vs ›	$1.82B	26.87x	33.52x	48.28x	46.71x
Novocure Ltd (NVCR)vs ›	$1.84B	N/A	434.55x	309.38x	391.85x
Astrana Health, Inc. (ASTH)vs ›	$1.84B	15.24x	17.23x	28.18x	30.02x
Palvella Therapeutics, Inc. (PVLA)vs ›	$1.86B	N/A	N/A	N/A	N/A
Generate Biomedicines, Inc. (GENB)vs ›	$1.79B	N/A	N/A	N/A	N/A
Novavax, Inc. (NVAX)vs ›	$1.87B	N/A	19.57x	82.87x	82.87x
Azenta, Inc. (AZTA)vs ›	$1.89B	177.04x	49.00x	83.04x	82.00x
BioLife Solutions, Inc. (BLFS)vs ›	$1.89B	N/A	539.27x	437.29x	621.70x
Agios Pharmaceuticals, Inc. (AGIO)vs ›	$1.89B	N/A	34.54x	34.54x	34.54x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics